{"id":"placebo-to-fdc-dor-isl","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL6068498","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and islatravir is a nucleoside reverse transcriptase inhibitor (NRTI) that work synergistically to block HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and integrating into host cells. This combination targets a critical step in the HIV replication cycle.","oneSentence":"A fixed-dose combination of doravirine and islatravir that inhibits HIV reverse transcriptase to suppress viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:35.458Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive adults"}]},"trialDetails":[{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT04233216","phase":"PHASE3","title":"Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-03-18","conditions":"HIV-1 Infection","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo to MK-8591A"],"phase":"phase_3","status":"active","brandName":"Placebo to FDC DOR/ISL","genericName":"Placebo to FDC DOR/ISL","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A fixed-dose combination of doravirine and islatravir that inhibits HIV reverse transcriptase to suppress viral replication. Used for HIV-1 infection in treatment-naive adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}